News|Articles|January 1, 2002

Infliximab and etanercept largely comparable in two real-world rheumatoid arthritis studies

Two new real-world comparisons of the tumor necrosis factor (TNF) blockers infliximab (Remicade) and etanercept (Enbrel) show that the two agents are highly comparable treatments for rheumatoid arthritis

Newsletter

Get the latest industry news, event updates, and more from Managed healthcare Executive.


Latest CME